Clinical Trial Update: Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study [Phase 2]

View source ↗

Summary

Phase 2 trial update for emapalumab in rapidly progressive interstitial lung disease associated with dermatomyositis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Interstitial Lung Disease
• Interstitial Lung Disease Due to Connective Tissue Disease

Drugs mentioned

• Emapalumab (emapalumab)

Snippet

Sponsor: University of Miami | Conditions: Dermatomyositis, Dermatomyositis Sine Myositis | Phase 2 | Status: NOT_YET_RECRUITING